High claudin-4 antigen expression in triple-negative breast cancer by the immunohistochemistry method

被引:5
|
作者
Naimi, Azar [1 ]
Zare, Nadereh [1 ]
Amjadi, Elham [2 ]
Soltan, Maryam [1 ]
机构
[1] Isfahan Univ Med Sci, Dept Pathol, Esfahan, Iran
[2] Poursina Hakim Digest Dis Res Ctr, Esfahan, Iran
来源
关键词
Claudin-4; immunohistochemistry; triple-negative breast cancer; JUNCTION PROTEINS CLAUDIN-3; ANDROGEN RECEPTOR; CARCINOMA;
D O I
10.4103/jrms.jrms_1389_20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Triple-negative breast cancer is a heterogeneous subtype of breast cancer. Claudin is an epithelial tight junctional protein, and also it is a receptor for clostridium perfringens enterotoxin and shows impairment of expression in several cancers. The chief purpose of this study is to assess the claudin-4 expression in triple-negative breast cancer (TNBC) Iranian patients and evaluate its correlation with some clinicopathological factors. Materials and Methods: In this study, 81 TNBC patients were evaluated for the claudin-4 expression by immunohistochemistry. The slides' staining intensity was examined and scored from 0 to 3. Then, slides were reviewed to assess the percentage of cells with membrane and cytoplasmic staining; the obtaining scores were 1-4. Finally, added the resulting two numbers from two stages, and the final number was a maximum of 7. Final scores of 0-3 were considered the low expression, and 4-7 were considered the high expression. Finally, the collected data were analyzed using the Chi-square test. Results: Eighty-one women with breast cancer and a mean age of 49 & PLUSMN; 12 years participated in the study. In 80% of the patients, there was a high expression of claudin-4 marker, and 20% had low expression. The expression level of the marker was not significantly correlated with age, tumor size, lymph node involvement, tumor grade, disease stage, Ki-67, and metastasis. Conclusion: The present study confirmed the high frequency of claudin-4 antigen expression in TNBC patients, and no significant correlation was observed between the expression of antigen and demographic or clinicopathological factors.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] High expression of claudin-4 in biliary carcinomas
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 404 - 404
  • [22] Significance of the vimentin expression in triple-negative breast cancer
    Yamashita, Nami
    Tokunaga, Eriko
    Kitao, Hiroyuki
    Tanaka, Kimihiro
    Taketani, Kenji
    Saeki, Hiroshi
    Aishima, Shinichi
    Oki, Eiji
    Morita, Masaru
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Expression of Dicer and Drosha in triple-negative breast cancer
    Passon, Nadia
    Gerometta, Anna
    Puppin, Cinzia
    Lavarone, Elisa
    Puglisi, Fabio
    Tell, Gianluca
    Di Loreto, Carla
    Damante, Giuseppe
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (04) : 320 - 326
  • [24] Androgen receptor expression in triple-negative breast cancer
    Glavynskyi, I.
    Dyatel, M.
    Zakhartseva, L.
    Guz, O.
    Zakhartsev, I.
    VIRCHOWS ARCHIV, 2017, 471 : S294 - S294
  • [25] EXPRESSION OF HORMAD1, A CANCER/TESTIS ANTIGEN, IN TRIPLE-NEGATIVE BREAST CANCERS WITH HIGH GENOMIC INSTABILITY
    Grigoriadis, A.
    Gazinska, P.
    Rasmussen, M.
    Isaksson, A.
    de Rinaldis, E.
    Mathew, S.
    Marra, P.
    Gillett, C.
    Pinder, S.
    Tutt, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 37 - 37
  • [26] Triple-Negative Breast Cancer
    Winkeljohn, Debra L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 861 - 863
  • [27] Triple-Negative Breast Cancer
    Hudis, Clifford A.
    CANCER JOURNAL, 2010, 16 (01): : 10 - 11
  • [28] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [29] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [30] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620